EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Honokiol Targeting SIRT3 : From Molecular Mechanisms to Therapeutic Opportunities

Feng Xiang, Zhimin Zhang, Yamei Li, Bohou Xia, Yingyan Liao, Chen Yang, Zhiqiang He, Limei Lin, Jingchen Xie iD

The FASEB Journal · 15.07.2025 · 39 (13)

DOI: 10.1096/fj.202501428r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2025-07. Verfasst von Feng Xiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China. Hauptthemen laut MEDLINE: Lignans, Sirtuin 3, Biphenyl Compounds. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 148 Literaturangaben. Gefördert von: The National Natural Science Foundation of China, The Discipline Construcion Project of Hunan University of Chinese Medicine, The Key Project of Education Bureau of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Honokiol (HKL), one of the major bioactive components of the traditional Chinese medicine Magnolia officinalis , has garnered significant attention because of its extensive pharmacological activities. Numerous studies have demonstrated that SIRT3 plays a crucial regulatory role in the disease intervention mechanisms mediated by HKL. HKL can bind to the SIRT3 protein, not only directly increasing its deacetylase activity but also forming a positive feedback loop by activating its transcription factors, thereby further promoting SIRT3 expression. This dual regulatory mechanism effectively restores the function of downstream proteins, activates intracellular protective mechanisms, and combats a variety of pathological processes, including aging, oxidative stress, inflammation, cell death, mitochondrial dysfunction, and metabolic disorders. It has shown broad prospects in the prevention and treatment of chronic diseases such as neurodegenerative diseases, cardiovascular diseases, degenerative bone and joint diseases, lung diseases, and metabolic disorders. Although HKL is a highly recognized SIRT3 activator, there is currently no comprehensive review systematically summarizing the research on HKL as a SIRT3 activator. This review comprehensively summarizes the research progress over the past decade since the discovery of HKL as a SIRT3 activator. Through in‐depth analysis of the literature, we focused on elucidating the biological functions of HKL through SIRT3 activation in various disease models and the signaling pathways involved. These findings emphasize the therapeutic development value and significant application potential of HKL as a SIRT3 activator, providing a theoretical basis for the development of natural products that target SIRT3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LignansSirtuin 3Biphenyl CompoundsHumansAnimalsNeurodegenerative DiseasesOxidative StressAllyl CompoundsPhenols

Stichwörter der Autor:innen

SIRT3deacetylationdegenerative diseasehonokiolmitochondrial dysfunction

Substanzen

honokiolLignansSirtuin 3Biphenyl CompoundsSIRT3 protein, humanAllyl CompoundsPhenols

Autor:innen und Institutionen

  • Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.

ORCID-Profile: Jingchen Xie

Förderung

  • The National Natural Science Foundation of China
  • The Discipline Construcion Project of Hunan University of Chinese Medicine
  • The Key Project of Education Bureau of Hunan Province
  • The Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine
  • National Natural Science Foundation of China

Zitieren

APA

Xiang, F., Zhang, Z., Li, Y., Xia, B., Liao, Y., Yang, C., He, Z., Lin, L., & Xie, J. (2025). Honokiol Targeting SIRT3 : From Molecular Mechanisms to Therapeutic Opportunities. The FASEB Journal, 39(13). https://doi.org/10.1096/fj.202501428r

Vancouver

Xiang F, Zhang Z, Li Y, Xia B, Liao Y, Yang C, et al. Honokiol Targeting SIRT3 : From Molecular Mechanisms to Therapeutic Opportunities. The FASEB Journal. 2025;39(13). doi:10.1096/fj.202501428r

BibTeX
@article{Xiang2025,
  author = {Xiang, Feng and Zhang, Zhimin and Li, Yamei and Xia, Bohou and Liao, Yingyan and Yang, Chen and He, Zhiqiang and Lin, Limei and Xie, Jingchen},
  title = {Honokiol Targeting SIRT3 : From Molecular Mechanisms to Therapeutic Opportunities},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {13},
  doi = {10.1096/fj.202501428r}
}
Kostenlos starten →